Single Arm, Two Phase, Multicenter Trial to Evaluating the Efficacy and Safety of the CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia
Latest Information Update: 16 Jul 2020
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications Acute nonlymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms EECNTL
- Sponsors Sinobioway Cell Therapy
Most Recent Events
- 13 Jul 2020 Planned End Date changed from 1 Nov 2019 to 1 Dec 2025.
- 13 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2019 New trial record